Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Piper Sandler Maintains Overweight on NextCure, Lowers Price Target to $13

Piper Sandler analyst Edward Tenthoff maintains NextCure (NASDAQ:NXTC) with a Overweight and lowers the price target from $21 to $13.
byBenzinga Newsdesk
May 23, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Piper Sandler analyst Edward Tenthoff maintains NextCure (NASDAQ:NXTC) with a Overweight and lowers the price target from $21 to $13.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0